04 December 2019
Visiongain has published a new pharma report Human Microbiome Therapeutics Market Forecast: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.
A specialist sector within the overall pharmaceutical industry, the human microbiome-therapeutic market is dominated by a relatively small number of companies. The market holds enormous opportunities for growth in key therapeutic areas. The human microbiome therapeutics pipeline is flooded with potential drug candidates. Majority of human microbiome therapeutics are in the early stage of the development. Approximately 60% of microbiome therapeutics candidates have not yet been evaluated in human clinical trials. most of the clinical trials regarding microbiome research were focused on gastrointestinal disorders, infectious disorders, metabolic disorders etc. Competition is expected to be most intense for these indications, whereas there are relatively fewer competitors focusing their research efforts cancer, migraine, hypertension and others.
This report profiled the selected companies: 4D Pharma, AOBiome Therapeutics, C3J Therapeutics, Caelus Health, Enterome Bioscience, Ferring Pharmaceuticals, Finch Therapeutics/Crestovo, IGEN BIOTECH GROUP, Immuron, Intrexon Corporation, MaaT Pharma, MatriSys Biosystem and other companies.
The lead analyst commented that “The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders. Although the market is expected to be dominated by a handful of companies, it still provides opportunities for companies looking to introduce innovative solutions to meet the chronic needs within the market. We note that future growth within microbiome therapeutics will likely be driven by innovation from smaller and mid-cap players, possibly in partnership with one of the major companies in the market.”
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The antibiotics market was valued at US$44,567.3 million in 2022 and is projected to grow at a CAGR of 4.15% during the forecast period 2023-2033.
31 January 2023
The global Clinical Trial Supplies market was valued at US$ 2,617.7 million in 2022 and is projected to grow at a CAGR of 9.32% during the forecast period 2023-2033.
31 January 2023
The global Meningococcal Vaccines market was valued at US$3,268.6 million in 2022 and is projected to grow at a CAGR of 6.32% during the forecast period 2023-2033.
31 January 2023
The global Human Microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25% during the forecast period 2023-2033.